Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

De La Rue agrees £263m takeover by US investment firm Atlas

(Sharecast News) - Banknote printer De La Rue said on Tuesday that it has agreed to be bought by US investment firm Atlas in a £263m deal. Under the terms of the acquisition, Atlas will pay 130p per share, which is a premium of approximately 19% to the closing share price on 11 December 2024, the last day before the start of the offer period.

De La Rue chief executive Clive Vacher said: "De La Rue has undergone a fundamental transformation since 2020, in which we have successfully delivered on our turnaround plan to create more efficient and agile operations, while enhancing profitability in our industry-leading currency business as demonstrated by the strength of our order book.

"Atlas is the right partner to take De La Rue into its next phase of growth. Most importantly, under Atlas's ownership we can ensure long-term stability for our customers and our people, and best position the business for its next chapter. I look forward to working closely with Atlas and both our teams to deliver on this exciting opportunity for De La Rue."

At 0940 BST, the shares were up 17.4% at 131.50p.

Steve Clayton, head of equity funds at Hargreaves Lansdown, said: "De La Rue is in the process of selling off its Authentication division, so Atlas will be acquiring a pure-play currency operation. The deal represents a premium of 19% to the share price immediately before the deal was first mooted and more than three times the level that the shares had sunk to in mid-2023.

"Investors will be relieved perhaps to see such a recovery. But those with longer teeth are more likely to remember that De La Rue's directors fought off an approach by French rival Oberthur back in 2010, an approach that was valued at over 900 pence per share. Whoops."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.